Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial † † Study presented in part at ESMO 2014 Congress, Madrid, Spain, 26–30 September 2014.
Titel:
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial † † Study presented in part at ESMO 2014 Congress, Madrid, Spain, 26–30 September 2014.
Auteur:
Lonardi, S. Sobrero, A. Rosati, G. Di Bartolomeo, M. Ronzoni, M. Aprile, G. Scartozzi, M. Banzi, M. Zampino, M.G. Pasini, F. Marchetti, P. Cantore, M. Zaniboni, A. Rimassa, L. Ciuffreda, L. Ferrari, D. Barni, S. Zagonel, V. Maiello, E. Rulli, E. Labianca, R.